Immuneering Corporation (IMRX) shares have skyrocketed by 39.16% to $1.99 as of noon on Friday, September 13, 2024, following the release of promising initial data from its Phase 2a clinical trial. The trial results, which showed a 40% overall response rate and an 80% disease control rate, have significantly boosted investor confidence. Short-term technical indicators reveal a strong upward momentum, with the current price well above the 5-day and 20-day moving averages of $1.40 and $1.20, respectively. The 9-day RSI is at 87.86%, indicating the stock is overbought, while the 5-day average volume has surged to 26.36M, far exceeding the 20-day average of 6.98M, reflecting heightened trading activity. The short-term MACD oscillator is positive, suggesting continued buying pressure. Long-term indicators also support this bullish trend, with the MACD showing strengthening buy signals. Overall, both short-term and long-term technicals align, suggesting sustained upward momentum for IMRX.